Twist Bioscience is in a violent, sustained uptrend that has taken the stock from a 52-week low of $23.30 to a current price of $166.99, a gain of 497.46% over the trailing year and 415.56% year-to-date. At $166.99, the stock is trading at approximately 99.8% of its 52-week range (52-week high of $167.02), meaning it is effectively pinned to its highs with essentially zero overhead resistance from prior price action. This positioning is the hallmark of a momentum leader but also signals extreme overextension, particularly given that the stock has nearly doubled in the last three months alone (+90.71%) and is up 296.93% over six months. The 52-week low of $23.30 sits roughly 86% below the current price, underscoring how far the stock has traveled and how much air is now beneath it.

Short-term momentum is accelerating rather than decelerating: the stock gained 17.28% in the past month versus a 0.96% decline in SPY, producing a relative strength of +18.24 percentage points over one month and an extraordinary +482.45 points over one year. The most recent session alone saw a 7.35% single-day advance on volume of roughly 3.07 million shares, confirming that buyers are still aggressively chasing the name into new highs. Critically, the 1-month trend (+17.28%) is directionally aligned with, not diverging from, the 1-year trend (+497.46%), which argues against a mean-reversion setup and instead suggests a momentum regime that remains intact, though the parabolic slope raises the probability of sharp, violent pullbacks. The stock's beta of 2.22 means it is roughly 122% more volatile than the broad market, so a 10% market drawdown could plausibly translate into a 20%+ move in TWST, a critical consideration for position sizing.

On key levels, the immediate resistance is the 52-week high at $167.02, just $0.03 above the current $166.99 close, so any breakout to new highs would be a fresh momentum signal with no historical reference points above. Support is layered: the most recent consolidation zone around $124-$128 (early September) is the first meaningful shelf, followed by the $100-$115 area from early August, with the 52-week low at $23.30 as the ultimate backstop. A breakdown below the $124 support would likely signal a momentum unwind toward the $100 region, while a clean break above $167 could invite further trend-following flows. The maximum drawdown figure of -25.54% over the period is a useful reminder that even within this massive uptrend, the stock has experienced a drawdown exceeding 25%, consistent with its 2.22 beta and the elevated short interest implied by a short ratio of 6.74 days.

Twist's revenue trajectory is clearly re-accelerating: the most recent quarter (ending 2026-03-31) delivered $110.72 million in revenue, up 19.31% year-over-year, versus $103.70 million in the prior quarter and $99.01 million in the quarter before that. The sequential progression from $96.06 million (Q3 2025) to $99.01 million to $103.70 million to $110.72 million shows consistent quarter-over-quarter growth, and the YoY growth rate of 19.31% compares favorably to the year-ago quarter's $92.79 million base. Revenue is split roughly evenly between NGS Tools ($57.44 million) and Antibody Discovery ($53.27 million), meaning the company is not overly dependent on a single product line, though the antibody discovery segment is the more differentiated, higher-value opportunity tied to the AI/partnership narrative. The key question for the investment case is whether this ~19% growth rate can inflect higher as AI-driven drug discovery partnerships scale, or whether it represents a mature run-rate for the current product portfolio.

Profitability remains the central fundamental weakness: the company reported a net loss of $44.02 million in the most recent quarter on $110.72 million of revenue, a net margin of -39.76%, and a trailing net margin of -20.63%. Gross margin is a genuine bright spot at 51.59% in the latest quarter, up from 49.60% a year earlier and 45.13% two years ago, demonstrating real operating leverage at the gross-profit line as the silicon-based platform scales. However, operating margin remains deeply negative at -41.42%, with operating income of -$45.86 million, as operating expenses of $102.99 million (including $19.70 million of R&D and $76.09 million of SG&A) still swamp gross profit of $57.12 million. The one quarter that showed positive net income ($20.39 million in Q3 2025) was driven by a $50.70 million non-operating other-income item, not by core operations, so investors should not mistake it for a profitability inflection.

On the balance sheet, Twist is well-capitalized but cash-consumptive: the current ratio stands at 3.64 and the debt-to-equity ratio is a modest 0.29, indicating low leverage and ample short-term liquidity, with $124.85 million of cash at the end of the most recent quarter. However, free cash flow is deeply negative at -$95.14 million on a trailing basis, with the latest quarter alone burning -$25.55 million of FCF (operating cash flow of -$17.56 million minus $7.99 million of capex), and cash declined from $150.99 million to $124.85 million sequentially. ROE of -16.42% and ROA of -13.09% confirm that the business is not yet generating positive returns on capital, and with stock-based compensation running at $18.94 million in the latest quarter, dilution remains a real cost to shareholders. The company can fund its current burn internally for several more quarters given its cash position and low debt, but a sustained FCF deficit of this magnitude means the path to self-funding profitability is still the single most important fundamental milestone to monitor.